Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124 | Synapse
March 15, 2026Open Access
Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124
Key Points
To assess the safety and efficacy outcomes of high-dose methotrexate across all age groups.
Analysis of data from the HDMTX European Registry
Review of treatment outcomes in various age groups
Examination of adverse effects associated with high-dose methotrexate
High-dose methotrexate shows favorable safety profiles in various ages
Efficacy rates demonstrate effectiveness across treatment age spectrum